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Abstract
Background: With an estimated 38 million people worldwide currently infected with human immunodeficiency virus (HIV),
and an additional 4.1 million people becoming infected each year, it is important to understand how this virus mutates and
develops resistance in order to design successful therapies.
Methodology/Principal Findings: We report a novel experimental method for amplifying full-length HIV genomes without
the use of sequence-specific primers for high throughput DNA sequencing, followed by assembly of full length viral
genome sequences from the resulting large dataset. Illumina was chosen for sequencing due to its ability to provide greater
coverage of the HIV genome compared to prior methods, allowing for more comprehensive characterization of the
heterogeneity present in the HIV samples analyzed. Our novel amplification method in combination with Illumina
sequencing was used to analyze two HIV populations: a homogenous HIV population based on the canonical NL4-3 strain
and a heterogeneous viral population obtained from a HIV patient’s infected T cells. In addition, the resulting sequence was
analyzed using a new computational approach to obtain a consensus sequence and several metrics of diversity.
Significance: This study demonstrates how a lower bias amplification method in combination with next generation DNA
sequencing provides in-depth, complete coverage of the HIV genome, enabling a stronger characterization of the
quasispecies present in a clinically relevant HIV population as well as future study of how HIV mutates in response to a
selective pressure.
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Introduction
The development of a variety of next generation sequencing
technologies – including Roche/454, Illumina/Solexa, Applied
Biosystems SOLiD, Helicos Heliscope, and Pacific Biosciences
Single Molecule Real Time (SMRT) sequencing – has made high
throughput DNA sequencing possible. Each of these next
generation sequencing methods offers differences in read length,
the number of reads obtained, and the intrinsic error rate, all of
which should be taken into account when choosing a specific
sequencing platform. While next generation sequencing has only
became commercially available in the past several years, it is
already making a huge impact in a variety of biological fields, for
example in sequencing of mammalian genomes and transcrip-
tomes, studying different aspects of plant biology by allowing in
depth characterization of the variability in these populations, and
investigating viral evolution [1,2,3,4,5].
However, utilizing next generation sequencing to perform such
studies poses numerous challenges. For example, library genera-
tion requires large quantities of DNA (mg) as starting material, and
the use of this technology has thus been limited to studying cells or
organisms where larger quantities of DNA can be readily isolated
or where polymerase chain reaction (PCR) is used to amplify small
quantities of DNA into sufficient quantities for library preparation.
However, PCR can introduce a layer of bias into a sample since
only sequences that contain significant homology with the primers
sequences will be amplified, which will in turn affect the resulting
analysis of diversity present in the sample. This study attempts to
address this issue by developing a low bias method for amplifying
small amounts of RNA and DNA - such as those isolated from
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13564
tissue, rare cells, or clinical samples of pathogens - into larger
quantities needed for next generation sequencing The resulting
DNA can then be processed into libraries compatible with all of
the aforementioned sequencing platforms. A further challenge is
posed by the specific sequencing technology employed. Read
length, sequencing error, and the amount of sequence obtained all
play a role in the estimation of sequence diversity and error, and
methods to account for all of these are constantly evolving. Here
we apply both a new nucleic acid amplification and computational
analysis that addresses the challenge of aligning next generation
sequence data to a poorly defined reference genome for
characterizing viral quasispecies.
The coupled approach potentially enables the characterization of
entire viral populations, particularly important when studying
viruses with a high mutation rate such as human immunodeficiency
virus (HIV). An estimated 38 million people worldwide are currently
infected with HIV, with an additional 4.1 million people becoming
infected each year [6]. HIV is a member of the lentivirus family that
infects cells found in the human immune system, primarily CD4+ T
cells, leading to acquired immune deficiency syndrome (AIDS). The
HIV genome consists of two positive strands of RNA that encode the
various structural, regulatory, and accessory proteins required for
HIV genome processing, integration, and replication inside infected
cells [7]. Upon entering the cell, the HIV genome is then processed
into double stranded DNA (dsDNA) via the enzymatic activity of
reverse transcriptase found in the viral particle, and this DNA then
integrates into the genome of the host cell. At this juncture, the
provirus will either remain latent, allowing the cell to continue its
normal functions, or will more often initiate rapid replication,
resulting in the production of large quantities of viral particles and
cell death [8]. Newly infected individuals tend to have relatively
homogenous viral populations; however, due the high rate of virus
production coupled with the error prone nature of reverse
transcription, chronically infected HIV+ patients possess a highly
heterogeneous viral population [9]. Additionally, on a global scale
HIV has diversified into subtypes that differ considerably in genetic
sequence [10], where subtype B is the predominant version in the
Americas and Europe. Recombination between subtypes can also
occur to generate circulating recombinant forms (CRF) of HIV [11].
Several important efforts have successfully employed 454
sequencing to examine different aspects of HIV biology [12]. In
the initial work in this area, Bushman and colleagues used 454
sequencing combined with DNA barcoding to identify and
quantify the frequency of rare HIV drug resistance mutations in
patient plasma samples [13]. Another study demonstrated the
utility of 454 deep sequencing technology to identify minor
sequence variants in selected pieces of the HIV genome, the
reverse transcriptase and HIV-1 protease genes, amplified using
HIV sequence-specific primers [14], and a follow up study
developed an algorithm for reconstructing the viral population
within the sequenced sample, providing a valuable tool for
studying the evolutionary dynamics of a viral population [15].
Another study used 454 sequencing to examine how a specific
region of HIV env varies between two distinct viral populations,
those infecting monocytes vs. T-lymphocytes [16]. Furthermore,
454 sequencing was used to study how a specific region of the HIV
envelope mutated in response to treatment with a CCR5 agonist
and to detect HIV that utilizes the CXC receptor 4, allowing for
the phenotyping of specific HIV strains [17,18]. More recently,
454 sequencing was used to characterize a recombinant form of
HIV between the B and F subtypes [19]. This method used an
HIV-based primer set to obtain 500-fold coverage of ,8400 bases
of the 9700 total that comprise the HIV genome.
The unprecedented read depth obtained using next generation
sequencing can thus provide a deeper understanding of the
variability present in an HIV population compared to traditional
sequencing and can be further used to understand the biology
behind HIV infection. However, the studies to date have utilized
PCR for sample preparation, which in addition to likely
amplifying a subset of the viral quasispecies also enabled
sequencing of only a portion of the HIV genome. Accordingly,
we have worked to develop a low bias method that, to our
knowledge, for the first time does not entail the use of viral
sequence specific primers and enables next generation sequencing
of the full HIV genome from a clinically relevant sample. In
addition, the methodology could generally be applied to analyze
any RNA-based virus without any prior sequence knowledge,
which would enable rapid characterization of viral outbreaks such
as influenza, West Nile, Ebola, and severe acute respiratory system
(SARS) [20]. Furthermore, the approach can enable the
characterization of full viral genomes over time, for example in
response to therapeutic intervention, allowing for more effective
and efficient design of treatments.
To date, only 454 next generation sequencing has been applied
to HIV. While both 454 and Illumina can enable rapid sequencing
of genomes and transcriptomes [1], there are two major
differences between the two technologies: read number and
length. 454 produces approximately 400,000 relatively long (100–
400 nt) reads per run (for each quad of a plate), with the number
of reads likely to increase somewhat with newer instruments. In
contrast, Illumina generates 10 to 25 million reads that currently
range from 36 to 72 bps in length per run (for each of 8 lanes on a
slide), with the option for reading both ‘‘paired ends’’ of a
fragment to double the sequence obtained from a run, and read
length with existing instruments is likely to continue growing. For
this study, we have chosen to use Illumina sequencing due to its
lower cost and increased coverage compared to 454 sequencing
(360 MB–2.2 GB vs. 40–160 MB of sequence per run). Although
the shorter Illumina read length enables less analysis of mutation
linkage in a genome, the sequence obtained per run is considerably
larger and thus enables a deeper analysis of a DNA sample, though
it does pose computational challenges that we also address in this
work.
In this study, a homogenous control population of HIV
consisting of the NL4-3 strain was used to develop low bias
amplification, Illumina sequencing, and computational analysis,
resulting in complete coverage of the entire HIV genome with on
average .40,000 bases per position. A heterogeneous, clinically
relevant population of HIV produced by CD4+ T cells taken from
a patient enrolled in a HIV clinical trial [21] was then analyzed.
After developing and implementing an iterative computational
method to determine a consensus sequence for this population,
nearly 20,000 bases per position were recovered. To quantify the
sequence diversity present in each sample, the base substitution
rate was calculated for each population, and as anticipated, the
clinical sample had higher diversity than the clonal sample on
average. This study thus describes new means for low bias dsDNA
amplification and preparation for sequencing on any platform,
including 454, ABI SOLiD, Heliscope and Pacific Biosciences
SMRT, coupled with computational reassembly and analysis of
full length viral genomes from clinical samples.
Results
The goal of this work is to develop a novel method for
amplifying viral RNA into large quantities of DNA suitable for
processing into Illumina (or other) libraries without relying on
Deep Sequencing of HIV
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PCR and primers that assume specific sequences are present
within the sample. By avoiding the use of virus-specific primers,
one can reduce the bias associated with this step and potentially
amplify the entire 9709 base pair HIV genome with unprece-
dented levels of coverage. Another challenge involved developing
a novel computational method for reconstructing a ‘‘master
sequence’’ for clinical patient samples with unknown sequences
from the resulting reads obtained from the Illumina sequencing.
To summarize these advances, the experimental portion of the
workflow of our novel method is detailed in Figure 1, while the
computational portion of the workflow is shown in Figure 2.
Development of a novel method for generation of
Illumina libraries from viral supernatants
Generation of an Illumina library requires large amounts of
dsDNA (mg), while isolation of RNA from HIV supernatants tends
to yield much lower quantites (ng). To address this issue, we
developed a novel set of experimental methods to generate
libraries from two different samples: a control homogeneous
sample and a heterogeneous clinically relevant HIV sample. To
generate the former, the canonical HIV strain NL4-3 [22] was
produced using our previously published transfection method [23],
and virus was collected after a propagation step. This sample
served as a control sequence for this study, as the resulting viral
population should contain essentially the same RNA sequence.
The second sample, containing a clinically relevant HIV
population, was derived from viral supernatant collected from an
in vitro culture of CD4+ T lymphocytes obtained from a patient
participating in a clinical trial. Specifically, VIRxSYS isolated
CD4+ T lymphocytes from the peripheral blood of a HIV+ study
subject as previously described [24], the T cells were later
activated using immobilized CD3/28 beads [24], and viral
supernatant was collected on day 9.
Figure 1. Flowchart of experimental methodology. Cell culture
supernatants containing viral particles was collected from HIV infected
cells. The RNA was extracted using the QIAamp Viral RNA Mini Kit and
coverted into large quantities of single stranded DNA using the WT-
Ovation Pico RNA Amplification System. The complementary strand for
the ssDNA was then synthesized using the WT-Ovation Exon Module.
The final step in the process involved using the Genomic DNA Sample
Prep Kit to produce an Illumina library.
doi:10.1371/journal.pone.0013564.g001
Figure 2. Flowchart of computational methodology. Once the
millions of Illumina reads were obtained, they were then aligned
against the 144 HIV-1 B genomes taken from the Los Alamos National
Lab database. These alignments produced regions of consensus for
each of these individual genomes which were then combined for the
final alignment using MAFFT, which is a multiple sequence alignment
program for nucleotide sequences.
doi:10.1371/journal.pone.0013564.g002
Deep Sequencing of HIV
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For both samples, we then used the QIAamp viral RNAMini Kit
to isolate viral RNA from cell culture supernatants, resulting in
30 ml of RNA with the concentration ranging between 1–5 ng/ml.
This RNA was then converted into large quantities of single
stranded DNA through the use of NuGEN WT-OvationTM Pico
RNA Amplification System, originally designed to process samples
for microarray analysis, which yielded between 150–350 ng/ml of
DNA with the total amount obtained ranging from 4.5 to 10.5 mg.
This ssDNA was then converted into double stranded DNA using
the WT-OvationTM Exon module, originally designed for cDNA
library synthesis, resulting in concentrations ranging between 300–
500 ng/ml with the total amount obtained ranging from 9 to 15 mg.
This dsDNA was then processed into an Illumina library using the
procedure outlined in the Illumina Genomic DNA Sample Prep kit
without performing the nebulization step, yielding libraries with a
concentration between 10 and 20 ng/ml. More details on this
experimental procedure can be found in the Methods sections and
detailed protocols are given in Supplemental File S1.
Validation of Illumina Library Generation Protocol. To
confirm that our method had worked for sequencing the entire
HIV genome for the control NL4-3 sample, the corresponding
library generated from that sample was then analyzed using paired
end Illumina sequencing, resulting in 21,655,108 reads (Table 1).
The NL4-3 sequence was then used as reference to map the
Illumina reads from the same samples using the program Mapping
and Assembly with Quality (MAQ), with the default parameters.
An initial analysis revealed that the error rate varied as a function
of position within the read (Methods, Supplemental Figure S1),
and the last 6 nucleotides were thus trimmed. The trimmed
paired-end reads were again aligned, and as detailed in Table 1,
71.75% of the reads mapped to the NL4-3 reference genome, with
59.15% mapping in pairs. 5.5% of the reads were possibly
contaminated with adapter sequence and 1.72% of the reads
mapped to the human genome.
The entire NL4-3 reference genome was recovered with
extremely high quality and depth of sequencing coverage, with
an average of 44,116 bases aligning for each position. The
maximum coverage was obtained at position 4832 of the reference
genome in the p31 int region of the pol gene at a read depth of
951,240 (Figure 3A). To quantify the diversity present in the reads,
the base substitution rate was calculated for each position, defined
as the fraction of bases that do not map to the expected base for a
given position (Figure 3B). The mean base substitution rate across
the genome was 0.919% for this sample, which correlates well with
the known sequencing error for the Illumina sequencing
process [25]. The mean base substitution rates were also calculated
for each of the genes of the HIV genome (gag, pol, env) as shown
in Table 2. We did not identify any biologically relevant indels in
this sample. While the gag and pol regions showed similar median
base substitution rates, the rate of the env gene was statistically
lower (Table 3).
Reconstruction of a heterogeneous, clinically relevant
HIV population
Having confirmed that our experimental method worked, we
then focused on the data obtained from sequencing the ‘‘clinical
sample,’’ which yielded over 14 million reads (Table 1). Unlike the
NL4-3 sample, no known HIV genome was associated with the
patient enrolled in the clinical trial. As a result, only a low number of
these reads mapped to a single reference genome. To address this
issue, we devised a novel methodology that would allow us to
reconstruct a ‘‘consensus sequence’’ consisting of the most abundant
sequence present for each region of the HIV genome for this specific
patient. In particular, to fully utilize the amount of data obtained
from our Illumina sequencing run as well as the sequence data
present in the Los Alamos National Labs HIV Database, we
developed an iterative strategy for enhanced mapping that utilized
larger amounts of known sequence data for building HIV sequences
(Figure 2). In this process, the reads were aligned against 414 known
subtype B HIV-1 genomes from the Los Alamos National
Laboratories using the iterative mapping method described in the
Methods section, and the master reference sequence for this sample
was constructed by combining regions of consensus where the
Illumina reads mapped to each of these genomes. By taking the
different regions of consensus that mapped to each of the 414
genomes, we were then able to generate our consensus sequence
that could then be used as our reference sequence for mapping our
Illumina reads. Our consensus sequence for this specific sample is
given in Supplemental File S2.
After generating this consensus sequence for the clinical sample,
we then were able to map the Illumina reads obtained against this
new master sequence developed using the HIV genomes taken
from the database, resulting in better coverage of the genome. On
average, 17,148 bases mapped to each position of this novel
reference HIV genome, corresponding to 46.95% of the total
reads aligning to the genome along with 36.38% mapping as pairs,
7.2% being possibly contaminated with adapter sequence, and
1.32% mapping to the human genome. Supplemental Figure S2
shows the alignment of the clonal and clinical samples. The
coverage as a function of position (Figure 3A) was maximal at
position 3921, where the depth reached 676,897 reads. Interest-
ingly, as observed for the clonal NL4-3 sample, this maximum
occurs in the pol gene, within the region that encodes the p15
RNase protein. Using the novel consensus sequence, the base
substitution rate for each position in the genome was again
calculated (Figure 3B). The mean base substitution rate for the
entire genome was 1.52%, significantly higher than the rate of the
clonal sample (p = 1.58E-10) and the expected error rate for
Illumina sequencing [25]. Similarly, higher base substitution rates
were observed for individual genes in this sample when compared
to the clonal population (Table 3). An interesting observation is
that, while in the clonal sample the env gene is the gene with lowest
mean variability (0.85%), in the clinical sample the env gene that
Table 1. Composition of Illumina Reads Obtained.
Sample
Total Number
of Reads
Number of reads
mapping to the
reference HIV
genome
Number of reads
mapping to the
reference HIV
genome in pairs
Number of reads with
possible adapter
contamination
Number of reads
mapping to the
human genome
NL4-3 (homogenous) 21,655,108 15,536,824 (71.7%) 12,808,867 (59.1%) 1,191,975 (5.5%) 371,752 (1.72%)
Patient T cells
(heterogeneous)
14,632,646 6,869,780 (46.9%) 5,323,304 (36.4%) 1,052,221 (7.2%) 203,690 (1.39%)
doi:10.1371/journal.pone.0013564.t001
Deep Sequencing of HIV
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13564
shows the most variability (1.71%) compared to the other genes for
this sample, consistent with env being the most variable region of
the HIV genome [26].
Computational analysis for insertion-deletion (indel) determi-
nation and identification is still in a very early stage of
development. Nevertheless, MAQ offers a very simple program
that aims to recover indels from the reads that had to be aligned
using the Smith-Waterman algorithm. This process is used when
one of the paired end reads maps but its partner does not. This
algorithm can then be applied to determine the spacing of the
Figure 3. A) Coverage (log of read depth) of the HIV genome for both clonal and clinical samples. B) Base substitution rates plots for the same two
samples. C) Magnified region of base substitution plot showing the location of the drug resistant mutations present in the clinical sample. The blue
line corresponds to the coverage for the homogenous NL4-3 sample and the red line corresponds to the coverage of the heterogeneous clinically
relevant HIV population. The average coverage was higher for the clonal sample than the clinical sample while the average base substitution rate was
higher for the clinical sample. Key for drug resistant mutations in figure 3C (number- gene:mutation (basepair location)): 1 – PR:L10F (2298), 2 –
PR:M46I (2411), 3- PR:I54V (2436), 4- PR:G73T (2487), 5- PR:I84V (2520), 6- PR:L90M (2548), 7- RT:M41L (2688), 8- RT:D67N (2766), 9- RT:K101H (2868),
10- RT:V106I (2883), 11- RT:V118I (2919), 12- RT:G190A (3135), 13- RT:L210W (3196), 14- RT:T215Y (3210), 15- RT:K219N (3222).
doi:10.1371/journal.pone.0013564.g003
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insertion or deletion required to map the latter. After filtering, we
were able to find two biological interesting indels in our sample,
which were mutations also found in the Los Alamos National Lab
HIV database when queried using basic local alignment search
tool (BLAST). One is a 6 bp deletion at position 6675, present in
2.44% of the reads that map in that site, and the other a 3 bp
deletion at the position 7321, with a relative fraction of 36.1%
(Table 4). Both of the mutations occurred in the env gene.
We also scanned the sequence obtained against Stanford
University HIV Drug Resistance Database [27] to determine
whether this clinically relevant sample contained drug resistance
mutations. The master sequence was confirmed by the database to
contain the appropriate, biologically relevant HIV genes, and
several drug resistant mutations were also identified. We found
several of these mutations present in the pol gene – specifically in
the protease and reverse transcription regions, , and these
mutations are listed in Table 5 and shown in Figure 3C along
with the associated base substitution rates.
Discussion
Numerous studies have previously used 454 next generation
DNA sequencing to analyze different aspects of HIV biology
[13,14,16,17,18,19,28,29,30]. However, these strong studies did
reveal some limitations of the underlying methodology – the use of
HIV specific primers that introduced a level of bias into the
sequencing data and the difficulty associated with amplifying the
entire 10,000 nucleotide HIV genome for analysis. Although it can
sometimes be useful to enrich for a target sequence when studying
larger, eurkaryotic genomes where coverage is otherwise limiting
[31,32], in the case of HIV, it would be advantageous to sequence
the entire genome to gain insights into the composition of complex
viral populations and investigate the dynamics of their evolution.
The method detailed in our work avoids the use of any HIV
sequence specific primers by using a combination of oligodT and
random hexamers that prime throughout the genome. Important-
ly, this method combined with Illumina sequencing yielded full
coverage of the HIV genome with unprecedented levels
(.17,0006) compared to prior studies.
To analyze the extent of coverage of both a simple and a more
complex sample, we sequenced a control viral sample, the
canonical NL4-3 strain, as well as a clinical sample consisting of
a heterogeneous HIV population. For the latter, we developed
new computational methods for constructing a consensus sequence
and characterizing the diversity of such populations. In both cases,
the entire HIV genome was recovered with unprecedented levels
of coverage (number of mapped bases at a position in the genome)
compared to previous reports. Interestingly, the degree of coverage
varied across the genome, though the shape of coverage
distribution curves was similar for both samples (Figure 3),
indicating that some bias may have been introduced by the use
of random hexamer primers and the mapping process to result in
different extents of very deep coverage. As expected, the coverage
of the clinical sample was lower than the clonal sample. This
difference can be attributed to a number of possible explanations.
First, certain reads obtained from the clinical sample will not map
to any of the known genomes present in the database due to the
diversity of the HIV population. Additionally, after generating the
consensus sequence, there will be reads that will not map to this
sequence because they are too divergent from the consensus
‘‘master’’ sequence despite previously mapping to some of the
individual genomes in the database.
As an initial measure of diversity, we calculated the base
substitution rates – defined as the fractions of bases that do not
map to the expected base for a given position – for both samples,
and the heterogeneous, clinically relevant HIV population was
statistically more diverse. As shown in Tables 2 and 3, the median
base substitution rate was significantly higher for all genes in the
clinical patient compared to the homogenous clonal sample.
Specifically, the base substitution rate for the env gene, the most
variable region of the HIV genome [26], was the highest for the
clinical sample, compared to 0.853% for the clonal sample.
Table 2. Mean base substitution rate for genes.
Sample
Mean base
substitution
rate for gag
gene
Mean base
substitution
rate for pol
gene
Mean base
substitution
rate for env
gene
NL4-3
(homogenous)
0.902% 0.961% 0.853%
Patient T cells
(heterogeneous)
1.459% 1.597% 1.707%
doi:10.1371/journal.pone.0013564.t002
Table 3. Statistical Comparison of Base Substitution Rates in
Different Genes**.
gag
clonal
pol
clonal
env
clonal
gag
clinical
pol
clinical
pol clonal 0.170
env clonal 1.29E-14 2.20E-16
gag clinical 3.75E-3 ND*** ND
pol clinical ND 0.0324 ND 0.0158
env clinical ND ND 2.15E-4 5.01E-7 2.20E-16
**p values are given in this table.
***ND - Not determined, as the mean base substitution rates were statistically
compared only for relevant pairs of samples.
doi:10.1371/journal.pone.0013564.t003
Table 4. Location and analysis of indels from clinical sample.
Location in
genome
Length and indel
sequence
Frequency (occurs
in % of reads)
6675 -6:TAGAAA 2.44%
7321 -3:GAA 36.1%
doi:10.1371/journal.pone.0013564.t004
Table 5. List of resistance mutation for the clinical sample*.
Known PR resistance mutations M46I (2411), I54V (2436), I84V (2520),
L90M (2548), L10F (2298), G73T (2487)
Known RT resistance mutations M41L (2688), D67N (2766), V118I (2919),
L210W (3196), T215Y (3210), K219N
(3222), K101H (2868), V106I (2883),
G190A (3135)
Known IN resistance mutations none
Mutations are listed by amino acid mutation within the specific gene with the
basepair position being given in parentheses.
doi:10.1371/journal.pone.0013564.t005
Deep Sequencing of HIV
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Additionally, in the clinical patient sample we observed two
biologically relevant indels. Further analysis of this rich data set
could yield more insight in the considerable sequence diversity of
different regions of the HIV due to the levels of coverage. For
instance, we were able to characterize the drug resistant nature of
our clinically relevant HIV population (Table 5), and this
information was consistent with the criteria for enrolling in the
clinical trial (i.e. the patient had failed at least 1 regimen of
HAART). Additionally, the generation of a consensus sequence for
a patient serves as a valuable resource when observing how
populations of HIV mutate over time.
One of the main limitations of using Illumina sequencing arises
when attempting to determine whether a base pair that does not
match the reference sequence is due to sequencing error or viral
mutation. A potential method for distinguishing the difference
between these two cases is to set a probability threshold based on
the location of the mismatch in the Illumina read, as the
sequencing error varies as a function of position within the read
(Supplemental Figure S1), and the frequency with which a given
mismatch is observed, where its appearance in numerous reads
would indicate that it reflects true viral diversity. For the clonal
sample, the error rate observed correlated well with previously
reported Illumina error rates [25]. In the case of the clinical
sample, however, it is more challenging to determine when a given
mismatch was due to the sequencing method or to viral diversity.
Additionally, it is possible that the mapping process used to
establish a consensus sequence also introducfes a layer of error
when assembling the consensus sequence. Therefore, while the
novel iteration approach enabled the generation of a consensus
sequence from .10 million short reads, we will explore this
method in depth in future studies to fully utilize the potential of
Illumina sequencing for studying viruses. Another alternative for
addressing these limitations is to use SOLiD sequencing, which
sequences each read in both directions – allowing for determina-
tion of when sequencing error occurs.
The experimental and computational methods developed here
could be harnessed to investigate numerous biological problems,
including how populations of HIV mutate over time in response to
selective pressures, such as HAART or antiviral genetic therapies.
In addition, a therapeutic pressure can result in the emergence of
resistance due to mutations distant from the target site [23], and
the ability to rapidly gain deep coverage of the entire genome
(Figure 3A) will thus generally aid studies of HIV evolution. An
example of such a therapy is Lexgenleucel-T, a cell-based therapy
consisting of a dose of 10 billion autologous CD4+ T lymphocytes
transduced ex vivo with the HIV-1 based lentiviral vector
VRX96TM, which encodes a 937 bp antisense sequence against
the env region of HIV. Its introduction into CD4+ T cells was
shown to inhibit HIV replication, and vector-transduced T cells
were subsequently tested in Phase I clinical trials [21,24,33]. This
sequencing method could be used to garner insights into the
efficacy of this and other potential anti-HIV therapies, and
knowledge gained from studying HIV evolution over time could
potentially be used to design more effective therapies.
More generally, these experimental and computational methods
can be used to study any DNA or RNA based virus with a known
sequence to allow for the alignment of the Illumina reads. In
addition, these methods could potentially be used to study
pathogens without a known sequence, though this application
would most likely require the development of methods for de novo
assembly of the resulting Illumina reads. Furthermore, these
methods can be applied to a diverse array of biological problems.
Previously, next generation sequencing required such large
amounts of starting material that it was applied to organisms
and cell lines where scale-up would not pose an issue. This work
will assist investigation of genomes and transcriptomes of cells and
organisms that are harder to culture and as a result generate
smaller quantities of genetic material available, such as primary
cells, stem cells, and other cell lines that are difficult to culture in
large quantities. Multiplexing of such samples to enable analysis of
multiple libraries mixed into the same sample for sequencing can
also render the process more cost effective and allow for the
analysis of more samples. The experimental methodology detailed
in this paper can also be used to prepare large quantities of dsDNA
for any ‘‘next generation’’ sequencing platform. For these various
reasons, this novel methodology expands the potential impact of
next generation sequencing technologies.
Methods
Generation of HIV samples and Isolation of RNA
Two different HIV samples were processed and sequenced
using Illumina technology in this study: a control virus produced
via a transfection process and clinical viral sample produced by T
cells obtained from an HIV+ patient participating in a study. The
former was the NL4-3 viral strain [22], produced using a
previously published transfection method [23,34], and represented
a homogenous viral population in which the viral genomes within
the population should be nearly identical in sequence. To generate
this virus, 12 mg of the sLTR plasmid was linearized using the
restriction enzyme Eco RI and rejoined using ligase to remove the
bacterial sequence present in plasmid as previously described [23].
HEK293Ts obtained from the American Type Culture Collection
(www.atcc.org) were then transfected with this viral genome along
with helper plasmids (3.5 mg of pcDNA3 IVS VSV-G, 5 mg of
pMDLg/pRRE, 1.5 mg of pRSV Rev and 2 mg of CLPIT Tat-
mCherry) to enhance production efficiency. The virus was
amplified on SupT1s for 6 days (corresponding to approximately
3 rounds of amplification) to further increase the viral titer. Viral
titer, determined as described previously [23], was approximately
40,000 IU/mL after the three rounds of amplification.
The second HIV sample, collected from in vitro culture of CD4+
T lymphocytes obtained from a patient participating in the
VRX96TM phase II clinical trial (NIH Clinical Trial:
NCT00131560) held by the VIRxSYS corporation, was antici-
pated to contain a heterogeneous HIV population. Patients
enrolled in this study had already failed at least one HAART
regimen and gave consent to for their cells to be used for research
purposes Specifically, the CD4+ T lymphocytes were isolated from
the peripheral blood from an HIV+ study subject as previously
described [24] and frozen as stocks. For this study, these cells were
thawed and allowed to recover overnight. The next day (Day 1),
these cells were activated using immobilized CD3/28 beads as
previously described [24], and on Day 9 supernatants from these
cultures were collected for RNA isolation. The sample analyzed
contained 425 ng/mL of p24 protein as determined using a p24
enzyme linked immunosorption assay. For samples, viral RNA was
isolated from 540 ml of supernatant using the QIAamp viral RNA
mini kit per manufacturer’s instructions (Qiagen) and eluted in
30 ml of buffer AVE. No DNAse treatment step was performed.
Double stranded DNA Synthesis from Viral RNA
To perform the processing necessary to produce an Illumina
library, the nanogram scale quantities of viral RNA obtained after
RNA extraction needed to be converted into microgram quantities
of double stranded DNA (dsDNA). To this end, the NuGEN WT-
OvationTM Pico RNA Amplification System, which is generally
intended for microarray applications, was initially used to generate
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large amounts of single stranded DNA from a small initial quantity
of RNA using a three step process following the manufacturer’s
instructions. For detailed methods, please see Supplemental File
S1. First, reverse transcription using Qiagen Sensiscript RT
(estimated error rate between 1 mutation every 1700 basepairs and
1 mutation every 30,000 basepairs) converted HIV’s RNA
genomes into single stranded DNA (ssDNA). This first strand
DNA synthesis reaction was initiated by a chimeric DNA/RNA
primer set that allowed for the binding of reverse transcriptase to
the RNA molecule. The DNA portion of the primer consisted of
either a random hexamer or a polyT region followed by a unique
RNA sequence that labeled the 59 prime end of newly synthesized
DNA molecule.
Next, second strand DNA synthesis was performed to generate a
complimentary strand to the ssDNA generated during the first
step. The final step in the process was the SPIATM amplification
step where a linear amplification process was performed on the
dsDNA produced, generating large quantities of single stranded
complimentary DNA (cDNA). This process requires DNA
polymerase with an estimated mean error rate of 1 mutation
every 100,000 basepairs.
Finally, to convert the purified cDNA into dsDNA, the WT-
OvationTM Exon module was used, in which a combination of
random primers and DNA polymerase was used to generate the
sense strand of the cDNA. This process requires DNA polymerase
with an estimated mean error rate of 1 mutation every 100,000
basepairs. The resulting dsDNA products were purified using the
QIAquick PCR purification kit with the modified protocol
described in Supplemental File S1. The concentration of the
resulting dsDNA was quantified using the ND-1000 spectropho-
tometer (Nanodrop) and confirmed using agarose gel electropho-
resis.
Preparation of DNA libraries for Illumina sequencing
The resulting dsDNA amplicons were then processed into a
library using the following procedure taken from the Genomic
DNA Sample Prep Kit (Illumina). No nebulization step was
required because the input amplicons already ranged in size from
300–600 bp, and a more detailed protocol can be found in
Supplemental File S1.
The size distribution and concentration of the Illumina libraries
were then assessed using the Bioanalyzer 2000 (Agilent) by the
University of California-Berkeley Functional Genomics Laborato-
ry. For the NL4-3 sample, the average fragment size was 181 bp
long, with a size distribution ranging from 120–210 bp in length.
For the clinical sample, the average fragment size was 151 bp long
with a size distribution ranging from 100–200 bp in length. A
small portion of each library was cloned into the pSC-B-amp/kan
plasmid using the Stratclone Blunt PCR Cloning Kit (Stratagene),
and the resulting plasmids were Sanger sequenced to confirm the
presence of HIV genome in these libraries. The resulting libraries
were then deep sequenced on an Illumina 1G Genome Analyzer
(Illumina) with paired end capability in the Vincent J. Coates
Genomics Sequencing Laboratory at University of California-
Berkeley. Read length was 36 base pairs.
Data Filtering and Alignment
The raw data obtained from the Illumina runs were then
processed using the default settings for base calling to ensure read
quality with reads containing more than two unidentifiable bases
were discarded, producing usable sequence data in standard
FASTQ format. The reads were then mapped against the HIV
reference genome that best represented the sample from where
they came from using MAQ 0.7.1 software (Li H: Maq:
Mapping and Assembly with Qualities. [http://maq.
sourceforge.net/index.shtml]) allowing up to 3 mismatches in the
first 24 bp of the read. A key requirement is to determine which
part of the read has the most quality to be considered for
population studies. Due to the chemistry of the sequencing
reaction, the bases sequenced at the end of a read tend to have
higher error rates, resulting in mismatches, indels, or ambiguously
identified bases (Ns). To address this issue, we computed the error
for each sequencing cycle in the NL4-3 control sample as shown in
Supplemental Figure S1. To minimize the sequencing error, the
last 6 bp of the reads were trimmed before analysis, resulting in
30 bp paired-end reads. This process has been shown to
significantly decrease the error rate per base pair when using
short reads [35]. This process allowed us to limit the number of
mismatches observed due to the Illumina process and focus on the
actual mutations due to viral evolution.
In contrast to the homogeneous control population of NL4-3, in
which the Illumina data were mapped directly to its known
sequence using the MAQ program, a new approach that
accounted for variation in the input sequences had to be developed
to reconstruct the clinically relevant, heterogeneous HIV popula-
tion from the Illumina data. That is, members of a viral
quasispecies obtained from an HIV+ patient will be highly
dissimilar from any given single HIV reference sequence due to
insertions, deletions and polymorphisms. Moreover, the quasis-
pecies complexity, combined with the very short length of the
reads, make de novo assembly of the full genomes impractical.
The millions of sequence reads were aligned against 414 distinct
HIV-1 subtype B genome entries in the public Los Alamos
National Labs HIV database (www.hiv.lanl.gov), and the reads
that aligned to each reference genome were then used to generate
new consensus sequences. That is, in the regions where reads
mapped, the resulting consensus sequence was inserted in place of
the corresponding region in the Los Alamos reference genome. In
regions with no mapped reads, the reference sequence remained
the same. All sequence data were again aligned to these new
consensus sequences, updated reference sequences were again
created, etc. As a result of five such iterations, there was a
significant improvement in the number of mapped reads and in
the fraction of the genome covered. The resulting consensus
sequences (one for each original Los Alamos reference genome)
were aligned to generate a final master consensus sequence. With
this method, we were able to reconstruct an almost complete
representative HIV genome of the clinical sample.
It was not possible to recover a particular region inside the env
gene using this method, and we thus used a PERL assembly script
to fill this region using overlapping reads. The final sequence was
verified by manual inspection comparing it with the mapped reads
by checking that the aligned reads overlapped without disconti-
nuities.
We then used this sequence as the reference for the subsequent
mapping and base pair substitution rate analysis. For both
samples, we calculated the read depth (number of reads that align
to a given position in the consensus) and base substitution rate
(fraction of bases that are different from the consensus sequence),
averaged across the entire genome and for specific genes of
interest. To identify indels, we used the Smith-Waterman
alignment found in the MAQ program. When one of the
paired-end reads mapped to the reference and the other did not,
MAQ tries to align the read in the expected region (based on
the distance) using the SW algorithm, allowing us to identify
significant indels in our sample, in particular specifically
recurrent indels that originate from population diversity and not
sequencing error.
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Statistical Analysis. Since the error rate fit a Poisson
distribution, we chose to use the Wilcoxon statistical test to
compare the median error rates between the clinical and clonal
samples and between the different genes for each samples. The
Wilcoxon statistical test was carried out using the R software
package (http://www.r-project.org/).
Supporting Information
Figure S1 Plot of base substitution rate for the clonal sample as a
function of read position. As shown in the plot, the first 6 base
pairs of the read contain the highest amount of error.
Found at: doi:10.1371/journal.pone.0013564.s001 (0.49 MB TIF)
Figure S2 Alignment of the clonal and clinical samples.
Found at: doi:10.1371/journal.pone.0013564.s002 (2.03 MB TIF)
File S1 Detailed protocols for reproducing methodology.
Found at: doi:10.1371/journal.pone.0013564.s003 (0.03 MB
DOC)
File S2 Master Sequence based on Illumina sequencing of the
clinical sample.
Found at: doi:10.1371/journal.pone.0013564.s004 (0.03 MB
DOC)
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